Skip to main content

Healthy Volunteer Study

19
Pipeline Programs
14
Companies
18
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
19
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 22 programs with unclassified modality

Competitive Landscape

14 companies ranked by most advanced pipeline stage

Genentech
GenentechCA - Oceanside
5 programs
5
AT-527Phase 11 trial
AT-527Phase 11 trial
AT-527 550 mg + cyclosporinePhase 11 trial
Drug: AT-527 + rosuvastatinPhase 1Small Molecule1 trial
Period 1: AT-527 550 mgPhase 11 trial
Active Trials
NCT04877769Completed24Est. Aug 2021
NCT05004415Completed6Est. Aug 2021
NCT04849299Completed24Est. May 2021
+2 more trials
Orion
OrionUK - Cambridge
3 programs
3
ODM-106Phase 1
TiotropiumPhase 1
salmeterol / fluticasone propionatePhase 1
Orion Pharma
Orion PharmaUK - Reading
3 programs
3
ODM-106Phase 11 trial
TiotropiumPhase 11 trial
salmeterol / fluticasone propionatePhase 11 trial
Active Trials
NCT02393950Completed16Est. Mar 2016
NCT03945344Completed20Est. Jun 2019
NCT01564199Completed20Est. Jun 2012
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
AZD8566Phase 11 trial
Active Trials
NCT00866385Completed21Est. Apr 2009
Biocorp
BiocorpFrance - Issoire
1 program
1
BEN8744Phase 11 trial
Active Trials
NCT06118385Completed76Est. Mar 2024
Humanetics Corp.
Humanetics Corp.MN - Roseville
1 program
1
BIO 300 Oral SuspensionPhase 11 trial
Active Trials
NCT06741345Completed56Est. Aug 2025
Comanche Biopharma
Comanche BiopharmaMA - Concord
1 program
1
CBP-4888Phase 11 trial
Active Trials
NCT05881993Completed45Est. May 2024
Cullgen
CullgenCA - San Diego
1 program
1
CG001419Phase 11 trial
Active Trials
NCT06636500Completed72Est. Dec 2025
Pfizer
PfizerNEW YORK, NY
1 program
1
Glasdegib Oral TabletPhase 11 trial
Active Trials
NCT03270878Completed12Est. Oct 2017
Kinoxis Therapeutics
Kinoxis TherapeuticsAustralia - Melbourne
1 program
1
KNX100Phase 11 trial
Active Trials
NCT04901078Completed57Est. Sep 2023
Traws Pharma
Traws PharmaPA - Newtown
1 program
1
TRX-100Phase 11 trial
Active Trials
NCT06757738Completed66Est. Jan 2025
Roche
RocheSTAVANGER NORWAY, Norway
3 programs
AT-527 550 mg + midazolamPHASE_1
Drug: AT-527 + rosuvastatinPHASE_1Small Molecule
Period 1: AT-527 550 mgPHASE_1
Innovation Pharmaceuticals
1 program
3M 1529 Adhesive TapeN/A1 trial
Active Trials
NCT04836572Completed60Est. Mar 2021
NewAmsterdam Pharma
NewAmsterdam PharmaNARRDEN, Netherlands
1 program
Fixed-Dose CombinationPHASE_11 trial
Active Trials
NCT06050291Completed28Est. Apr 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
CullgenCG001419
Humanetics Corp.BIO 300 Oral Suspension
Traws PharmaTRX-100
NewAmsterdam PharmaFixed-Dose Combination
BiocorpBEN8744
Comanche BiopharmaCBP-4888
Kinoxis TherapeuticsKNX100
GenentechDrug: AT-527 + rosuvastatin
GenentechAT-527
GenentechAT-527
GenentechAT-527 550 mg + cyclosporine
GenentechPeriod 1: AT-527 550 mg
Orion PharmaTiotropium
PfizerGlasdegib Oral Tablet
Orion PharmaODM-106

Showing 15 of 18 trials with date data

Clinical Trials (18)

Total enrollment: 652 patients across 18 trials

A Phase 1 Study of CG001419 Administered Orally in Healthy Subjects

Start: Jan 2025Est. completion: Dec 202572 patients
Phase 1Completed
NCT06741345Humanetics Corp.BIO 300 Oral Suspension

Phase 1 BIO 300 Oral Suspension

Start: Dec 2024Est. completion: Aug 202556 patients
Phase 1Completed

A Clinical Study Aiming to Assess Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TRX-100 in Healthy Volunteers

Start: Aug 2024Est. completion: Jan 202566 patients
Phase 1Completed
NCT06050291NewAmsterdam PharmaFixed-Dose Combination

Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and Ezetimibe

Start: Jan 2024Est. completion: Apr 202428 patients
Phase 1Completed

Study Investigating the Safety, Tolerability, PK and Food Effect of BEN8744.

Start: Aug 2023Est. completion: Mar 202476 patients
Phase 1Completed

Study of CBP-4888 in Healthy, Non-Pregnant Female Subjects

Start: May 2023Est. completion: May 202445 patients
Phase 1Completed

A Phase 1 Study Investigating the Safety, Tolerability and Pharmacokinetics of KNX100 in Healthy Volunteers

Start: Apr 2022Est. completion: Sep 202357 patients
Phase 1Completed
NCT05154123GenentechDrug: AT-527 + rosuvastatin

Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998)

Start: Nov 2021Est. completion: Dec 202129 patients
Phase 1Completed

Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998)

Start: Jul 2021Est. completion: Aug 20216 patients
Phase 1Completed

Bronchopulmonary PK of AT-527 (R07496998)

Start: Apr 2021Est. completion: Aug 202124 patients
Phase 1Completed
NCT04849299GenentechAT-527 550 mg + cyclosporine

Effect of Cyclosporine on the Pharmacokinetics (PK) of AT-527 (R07496998)

Start: Apr 2021Est. completion: May 202124 patients
Phase 1Completed
NCT04784000GenentechPeriod 1: AT-527 550 mg

Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527

Start: Mar 2021Est. completion: Apr 202120 patients
Phase 1Completed

Effect of Charcoal on Gastrointestinal Absorption of Tiotropium

Start: May 2019Est. completion: Jun 201920 patients
Phase 1Completed
NCT03270878PfizerGlasdegib Oral Tablet

Glasdegib Absolute Bioavailability Study

Start: Sep 2017Est. completion: Oct 201712 patients
Phase 1Completed

Safety, Tolerability,Pharmacokinetics and Pharmacodynamics of ODM-106 in Healthy Volunteers

Start: Mar 2015Est. completion: Mar 201616 patients
Phase 1Completed
NCT01564199Orion Pharmasalmeterol / fluticasone propionate

Phase I Pharmacokinetic Study (SALBLOCK)

Start: Apr 2012Est. completion: Jun 201220 patients
Phase 1Completed

AZD8566 Food Effect/Microtracer Study

Start: Mar 2009Est. completion: Apr 200921 patients
Phase 1Completed

An Open-label, Non Significant Risk, Adhesive Wear Validation Study for the On Body Drug Delivery Device Component of the SQIN-01 Furosemide Infusor (Infusor Device)

Start: Jan 2021Est. completion: Mar 202160 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

14 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.